Jefferies Cuts Price Target on Akorn (AKRX) to $24; Reiterates Buy
- Wall Street surges to new highs; transports set record
- lululemon athletica (LULU) Tops Q3 EPS by 4c; Adj.-Comps Outpaced Views
- Abbott (ABT) Files Complaint to Terminate Alere (ALR) Acquisition
- Costco Wholesale (COST) Tops Q1 EPS by 5c; Comps Up 1%, 2% Ex-Gas
- After-Hours Stock Movers 12/07: (VYGR) (LULU) (HRB( Higher; (OHRP) (VRNT) (CMTL) Lower (more...)
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
Jefferies maintained a Buy rating on Akorn (NASDAQ: AKRX), and cut the price target to $24.00 (from $35.00), following the company's 3Q earnings report. Jefferies lowered estimates as re-inspection issues create more uncertainty. Assuming a 6 month delay expected revenues from pipeline products have been cut by $30M to $55M next year and FY17 total revenues and EPS were adjusted to $1.19B and $2.46 (vs $1.22B & $2.56).
Analyst David Steinberg commented, "Q3 revs & EPS were $17M & $0.02 ahead of consensus despite higher R&D spend & lower gross margin. The results however were overshadowed by the disclosure that the Decatur plant needs to be re-inspected which could result in the delay of 10 (out of 25 expected) ANDA approvals by 1Q17 and a DOJ probe on generic drug price collusion. The sharp 18% selloff (vs 4% for XBI) does not seem fully warranted in our view particularly as AKRX was not named in the DOJ probe."
Shares of Akorn closed at $20.27 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wedbush Raises Price Target on Francesca's (FRAN) Following 3Q Report
- Sigma Designs (SIGM): Revenue Headwinds Drive PT Cut - Baird
- Oppenheimer Raises Price Target on NeuroDerm (NDRM) to $30 After Meeting with FDA
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change
Related EntitiesJefferies & Co, Earnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!